Biological effects of a de novo designed myxoma virus peptide analogue: Evaluation of cytotoxicity on tumor cells

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Istivan, Taghrid S ^a   Pirogova, Elena ^a   Gan, Emily ^a   Almansour, Nahlah M ^a   Coloe, Peter J ^a   Cosic, Irena ^a  

^a RMIT UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARGINYLARGINYLMETHIONYLMETHIONYLVALINE; DIMETHYL SULFOXIDE; MYXOMA VIRUS PEPTIDE DERIVATIVE; PEPTIDE DERIVATIVE; PROTEIN KINASE B; UNCLASSIFIED DRUG; LIPOCORTIN 5; PEPTIDE; PROPIDIUM IODIDE; VIRUS PROTEIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG SCREENING; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MATHEMATICAL MODEL; MELANOMA CELL; MOUSE; MYXOMA VIRUS; NONHUMAN; NUCLEOTIDE SEQUENCE; RESONANT RECOGNITION MODEL; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; ANIMAL; BIOLOGY; CELL DEATH; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; CONFOCAL MICROSCOPY; DRUG EFFECT; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; NEOPLASM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

MURINAE; MYXOMA VIRUS;

ANIMALS; ANNEXIN A5; APOPTOSIS; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; COMPUTATIONAL BIOLOGY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MICE; MICROSCOPY, CONFOCAL; MODELS, MOLECULAR; MYXOMA VIRUS; NEOPLASMS; PEPTIDES; PHOSPHORYLATION; PROPIDIUM; PROTO-ONCOGENE PROTEINS C-AKT; VIRAL PROTEINS;

EID: 80052910900     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024809     Document Type: Article

References (39)

1. Aghi M, Martuza RL, (2005) Oncolytic viral therapies: the clinical experience. Oncogene 24: 7802-7816.
2. Harrington KJ, Pandha HS, Vile RG, (2008) Poxviruses as immunomodulatory cancer therapeutics. In: Harrington K, Pandha H, Vile R, editors. Viral therapy of cancer West Sussex John Wiley & Sons Ltd pp. 95-114.
3. Everts B, Van Der Poel H, (2005) Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Ther 12: 141-161.
4. Carew JF, Kooby DA, Halterman MW, Kim SH, Federoff HJ, et al. (2001) A novel approach to cancer therapy using an oncolytic herpes virus to package amplicons containing cytokine genes. Mol Ther 4: 250-256.
5. Fielding AK, (2005) Measles as a potential oncolytic virus. Rev Med Virol 15: 135-142.
6. Lun X, Yang W, Alain T, Shi ZQ, Muzik H, et al. (2005) Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas. Cancer Res 65: 9982-9990.
7. Stanford MM, Shaban M; Barret JW, Werden SJ, Gilbert P, et al. (2008) Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo. Mol Ther 16: 52-59.
8. Fenner F, Ross J, (1994) Myxomatosis. In: Thompson GV, King CM, editors. The European rabbit, the history and biology of a successful colonizer Oxford Oxford University Press pp. 205-239.
9. Wang G, Barret J, Stanford M, Werden S, Johnston J, et al. (2006) Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. PNAS 103: 4640-4645.
10. Werden SJ, McFadden G, (2008) The role of cell signalling in poxvirus tropism: the case of the M-T5 host range protein of myxoma virus. Biochimica et Biophysica Acta 1784: 228-237.
11. Sypula J, Wang F, Ma Y, Bell J, McFadden G, (2004) Myxoma virus tropism in human tumor cells. Gene Ther Mol Biol 8: 103-14.
12. Mossman K, Lee SF, Barry M, Boshkov L, MaFadden G, (1996) Disruption of M-T5, a novel myxoma virus gene member of the poxvirus host range superfamily, results in dramatic attenuation of myxomatosis in infected European rabbits. J Virol 70: 4394-4410.
13. Johnston J, Wang G, Barrett J, Nazarian S, Colwill K, et al. (2005) Myxoma virus M-T5 protects infected cells from the stress of cell cycle arrest through its interaction with host cell cullin. J Virol 79: 10750-10763.
14. Park YJ, Chang LC, Liang JF, Moon C, Chung CP, et al. (2005) Nontoxic membrane translocation peptide from protamine, low molecular weight protamine (LMWP), for enhanced intracellular protein delivery: in vitro and in vivo study. FASEB J 19: 1555-1557.
15. Schmidt MM, Wittrup KD, (2009) A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther 8: 2861-2871.
16. Cosic I, (1994) Macromolecular bioactivity: is it resonant interaction between molecules? Theory and Applications. IEEE Trans. On BME 41: 1101-1114.
17. Cosic I, (1997) The Resonant recognition model of macromolecular bioactivity: theory and applications. In Meier T, Saluz HP, editors. Biomethods. Basel: Birkhauser Verlag: Vol 9.
18. Pirogova E, Fang Q, Akay M, Cosic I, (2002) Investigation of the structure and function relationships of oncogene proteins. Proc IEEE 90: 1859-1868.
19. Cosic I, Hodder AN, Aguilar MI, Hearn MT, (1991) Resonant recognition model and protein topography: model studies with myoglobin, hemoglobin and lysozyme. Eur J Biochem 198: 113-119.
20. Cosic I, Hearn MTW, (1992) Studies on protein-DNA interactions using the resonant recognition model: application to repressors and transforming proteins. Eur J Biochem 205: 613-619.
21. Cosic I, (1995) Spectroscopy for fun and profit,. Nature Biotech; 13: 236-238.
22. Cosic I, Drummond AE, Underwood JR, Hearn MTW, (1994) In vitro inhibition of the actions of basic FGF by a novel 16 amino cid peptide. Mol Cell Biochem 130: 1-9.
23. Murakami M, (2000) Resonant recognition model of neuropeptide Y family: hot spot amino acid distribution in the sequence. J Prot Chem 19: 609-613.
24. De Trad CH, Fang Q, Cosic I, (2000) The resonant recognition model (RRM) predicts amino acid residues in highly conservative regions of the hormone prolactin (PRL). Biophysical Chemistry 84: 149-157.
25. De Trad CH, Fang Q, Cosic I, (2002) Protein sequences comparison based on the wavelet transform approach. Protein Engineering 15: 193-203.
26. Krsmanovic V, Biquard JM, Sikorska-Walker M, Cosic I, Desgranges C, et al. (1998) Investigation into the cross-reactivity of rabbit antibodies raised against nonhomologous pairs of synthetic peptides derived from HIV-1 gp120 proteins. J Peptide Res 52: 410-420.
27. Veljkovic I, Slavic M, (1972) General model of pseudopotentials. Physical Review Let 29: 105-108.
28. Pirogova E, Vojisavljevic V, Fang J, Cosic I, (2006) Computational analysis of DNA photolyases using digital signal processing methods. Molecular Simulation 32: 1195-1203.
29. Cosic I, Pirogova E, (2007) Bioactive peptide design using the resonant recognition model. Nonlinear Biomedical Physics 1 (7) doi:10.1186/1753-4631-1-7.
30. Kandouz M, Gompel A, Therwath A, (1996) bcl-2 proto-oncogene, apoptosis and oncogenesis: an overview. Int J Oncol 9: 563-566.
31. Paez J, Sellers WR, (2003) PI3K/PTEN/AKT pathway: a critical mediator of oncogenic signaling. Cancer Treat Res 115: 145-167.
32. Pirogova E, Istivan T, Gan E, Cosic I, (2011) Advances in Methods for Therapeutic Peptide Discovery, Design and Development. Current Pharmaceutical Biotechnology 12 (8): 1117-1127.
33. Bredesen DE, (2000) Apoptosis: overview and signal transduction pathways. J Neurotrauma 17: 801-810.
34. Katoch B, Sebastian S, Sahdev S, Padh H, Hasnain SE, et al. (2002) Programmed cell death and its clinical implications. Indian J Exp Biol 40: 513-524.
35. Debatin KM, (2004) Apoptosis pathways in cancer and cancer therapy. Cancer Immunol Immunother 53: 153-159.
36. Shmulevitz M, Marcato P, Lee PWK, (2005) Unshackling the links between reovirus oncolysis, Ras signaling, translational control and cancer. Oncogene 24: 7720-7728.
37. Sperandio S, de Belle I, Bredesen DE, (2000) An alternative, non apoptotic form of programmed cell death. Proc Natl Acad Sci USA 97: 14376-14381.
38. Franke TH, Hornik CP, Segev L, Shostak GA, Sugimoto C, (2003) PI3K/Akt and apoptosis: size matters. Oncogene 22: 8983-8998.
39. Zanon M, Piris A, Bersani I, Vegetti C, Molla A, et al. (2004) Apoptosis protease activator protein-1 expression is dispensable for response of human melanoma cells to distinct proapoptotic agents. Cancer Res 64: 7386-7394.